Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entera Bio (ENTX) Change in Receivables (2019 - 2024)

Entera Bio has reported Change in Receivables over the past 6 years, most recently at -$7000.0 for Q4 2024.

  • For the quarter ending Q4 2024, Change in Receivables changed N/A year-over-year to -$7000.0, compared with a TTM value of $69000.0 through Dec 2025, down 45.24%, and an annual FY2025 reading of -$126000.0, down 200.0% over the prior year.
  • Change in Receivables came in at -$7000.0 for Q4 2024, down from $76000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $278000.0 in Q1 2020 to a low of -$301000.0 in Q4 2020.
  • Median Change in Receivables over the past 5 years was $13000.0 (2022), compared with a mean of -$10133.3.
  • The sharpest move saw Change in Receivables tumbled 903.7% in 2023, then skyrocketed 362.07% in 2024.
  • Over 5 years, Change in Receivables stood at -$301000.0 in 2020, then surged by 77.08% to -$69000.0 in 2021, then soared by 118.84% to $13000.0 in 2022, then plummeted by 323.08% to -$29000.0 in 2023, then skyrocketed by 75.86% to -$7000.0 in 2024.
  • Per Business Quant, the three most recent readings for ENTX's Change in Receivables are -$7000.0 (Q4 2024), $76000.0 (Q3 2024), and $57000.0 (Q2 2024).